The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PD-L1 Biomarker Testing Market Research Report 2025
Synopsis
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The global PD-L1 Biomarker Testing market was valued at US$ 1470.5 million in 2023 and is anticipated to reach US$ 14870 million by 2030, witnessing a CAGR of 38.7% during the forecast period 2024-2030.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
Report Scope
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-L1 Biomarker Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The global PD-L1 Biomarker Testing market was valued at US$ 1470.5 million in 2023 and is anticipated to reach US$ 14870 million by 2030, witnessing a CAGR of 38.7% during the forecast period 2024-2030.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
Report Scope
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segment by Application
Hospital
Diagnostic Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-L1 Biomarker Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 PD-L1 (22C3)
1.2.3 PD-L1(28-8)
1.2.4 PD-L1 (SP142)
1.2.5 PD-L1 (SP263)
1.2.6 Other
1.3 Market by Application
1.3.1 Global PD-L1 Biomarker Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-L1 Biomarker Testing Market Perspective (2019-2030)
2.2 PD-L1 Biomarker Testing Growth Trends by Region
2.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PD-L1 Biomarker Testing Historic Market Size by Region (2019-2024)
2.2.3 PD-L1 Biomarker Testing Forecasted Market Size by Region (2025-2030)
2.3 PD-L1 Biomarker Testing Market Dynamics
2.3.1 PD-L1 Biomarker Testing Industry Trends
2.3.2 PD-L1 Biomarker Testing Market Drivers
2.3.3 PD-L1 Biomarker Testing Market Challenges
2.3.4 PD-L1 Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PD-L1 Biomarker Testing Players by Revenue
3.1.1 Global Top PD-L1 Biomarker Testing Players by Revenue (2019-2024)
3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2019-2024)
3.2 Global PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PD-L1 Biomarker Testing Revenue
3.4 Global PD-L1 Biomarker Testing Market Concentration Ratio
3.4.1 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-L1 Biomarker Testing Revenue in 2023
3.5 PD-L1 Biomarker Testing Key Players Head office and Area Served
3.6 Key Players PD-L1 Biomarker Testing Product Solution and Service
3.7 Date of Enter into PD-L1 Biomarker Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-L1 Biomarker Testing Breakdown Data by Type
4.1 Global PD-L1 Biomarker Testing Historic Market Size by Type (2019-2024)
4.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2025-2030)
5 PD-L1 Biomarker Testing Breakdown Data by Application
5.1 Global PD-L1 Biomarker Testing Historic Market Size by Application (2019-2024)
5.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PD-L1 Biomarker Testing Market Size (2019-2030)
6.2 North America PD-L1 Biomarker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America PD-L1 Biomarker Testing Market Size by Country (2019-2024)
6.4 North America PD-L1 Biomarker Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PD-L1 Biomarker Testing Market Size (2019-2030)
7.2 Europe PD-L1 Biomarker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe PD-L1 Biomarker Testing Market Size by Country (2019-2024)
7.4 Europe PD-L1 Biomarker Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 Biomarker Testing Market Size (2019-2030)
8.2 Asia-Pacific PD-L1 Biomarker Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PD-L1 Biomarker Testing Market Size (2019-2030)
9.2 Latin America PD-L1 Biomarker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America PD-L1 Biomarker Testing Market Size by Country (2019-2024)
9.4 Latin America PD-L1 Biomarker Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 Biomarker Testing Market Size (2019-2030)
10.2 Middle East & Africa PD-L1 Biomarker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Detail
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies PD-L1 Biomarker Testing Introduction
11.1.4 Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.1.5 Agilent Technologies Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche PD-L1 Biomarker Testing Introduction
11.2.4 Roche Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck PD-L1 Biomarker Testing Introduction
11.3.4 Merck Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Introduction
11.4.4 Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca PD-L1 Biomarker Testing Introduction
11.5.4 AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Detail
11.6.2 Ono Pharmaceutical Business Overview
11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Introduction
11.6.4 Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.6.5 Ono Pharmaceutical Recent Development
11.7 Regeneron
11.7.1 Regeneron Company Detail
11.7.2 Regeneron Business Overview
11.7.3 Regeneron PD-L1 Biomarker Testing Introduction
11.7.4 Regeneron Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.7.5 Regeneron Recent Development
11.8 Innovent
11.8.1 Innovent Company Detail
11.8.2 Innovent Business Overview
11.8.3 Innovent PD-L1 Biomarker Testing Introduction
11.8.4 Innovent Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.8.5 Innovent Recent Development
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Detail
11.9.2 Hengrui Medicine Business Overview
11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Introduction
11.9.4 Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.9.5 Hengrui Medicine Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Detail
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Introduction
11.10.4 Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2019-2024)
11.10.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
